Literature DB >> 23233154

Genetic and epigenetic alterations of myeloproliferative disorders.

Jelena D Milosevic1, Robert Kralovics.   

Abstract

The classical BCR-ABL negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are clonal hematopoietic disorders characterized by excessive production of terminally differentiated myeloid cells. In MPN patients, the disease can progress to secondary myelofibrosis or acute myeloid leukemia. Clonal hematopoiesis, disease phenotype, and progression are caused by somatically acquired genetic lesions of genes involved in cytokine signaling, RNA splicing, as well as epigenetic regulation. This review provides an overview of point mutations and cytogenetic lesions associated with MPN and addresses the role of these somatic lesions in MPN disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233154     DOI: 10.1007/s12185-012-1235-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  160 in total

1.  Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.

Authors:  Sabina I Swierczek; Donghoon Yoon; Christine Bellanné-Chantelot; Soo Jin Kim; Cécile Saint-Martin; Francois Delhommeau; Albert Najman; Josef T Prchal
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

2.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

3.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Authors:  Joannah Score; Claire Hidalgo-Curtis; Amy V Jones; Nils Winkelmann; Alison Skinner; Daniel Ward; Katerina Zoi; Thomas Ernst; Frank Stegelmann; Konstanze Döhner; Andrew Chase; Nicholas C P Cross
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

4.  A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.

Authors:  Anne Stidsholt Roug; Charlotte Guldborg Nyvold; Caroline Juhl-Christensen; Mariann Christensen; Susanne Schnittger; Peter Hokland
Journal:  Eur J Haematol       Date:  2011-08-11       Impact factor: 2.997

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

Authors:  Michael A Caligiuri; Roger Briesewitz; Jianhua Yu; Lisheng Wang; Min Wei; Kristy J Arnoczky; Trent B Marburger; Jing Wen; Danilo Perrotti; Clara D Bloomfield; Susan P Whitman
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

7.  CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

Authors:  Carola Reindl; Hilmar Quentmeier; Konstantin Petropoulos; Philipp A Greif; Tobias Benthaus; Bob Argiropoulos; Gudrun Mellert; Sridhar Vempati; Justus Duyster; Christian Buske; Stefan K Bohlander; Keith R Humphries; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113

9.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

10.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  28 in total

1.  Focal 18F-FDG uptake in bone marrow on PET/CT in a patient with JAK2 mutation without overt myeloproliferative neoplasm.

Authors:  Akihito Fujimi; Yuji Kanisawa; Shinya Minami; Yusuke Kamihara; Sari Iwasaki
Journal:  Int J Hematol       Date:  2013-11-26       Impact factor: 2.490

2.  A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.

Authors:  Kenji Oritani; Shinichiro Okamoto; Tetsuzo Tauchi; Shigeki Saito; Kohshi Ohishi; Hiroshi Handa; Katsuto Takenaka; Prashanth Gopalakrishna; Taro Amagasaki; Kazuo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2015-02-01       Impact factor: 2.490

Review 3.  Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis.

Authors:  Kazuki Okuyama; Jun Ogata; Natsuko Yamakawa; Bidisha Chanda; Ai Kotani
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

4.  JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Authors:  Yoko Edahiro; Soji Morishita; Kochi Takahashi; Yumi Hironaka; Yuriko Yahata; Yoshitaka Sunami; Shuichi Shirane; Miyuki Tsutsui; Masaaki Noguchi; Michiaki Koike; Kiyotoshi Imai; Keita Kirito; Naohiro Noda; Yuji Sekiguchi; Satoshi Tsuneda; Akimichi Ohsaka; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

Review 5.  Normal and leukemic stem cell niches: insights and therapeutic opportunities.

Authors:  Koen Schepers; Timothy B Campbell; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-03-05       Impact factor: 24.633

6.  Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.

Authors:  Yasuhiro Taniguchi; Hirokazu Tanaka; Espinoza J Luis; Kazuko Sakai; Takahiro Kumode; Keigo Sano; Kentarou Serizawa; Shinya Rai; Yasuyoshi Morita; Hitoshi Hanamoto; Kazuo Tsubaki; Kazuto Nishio; Itaru Matsumura
Journal:  Int J Hematol       Date:  2017-08-05       Impact factor: 2.490

Review 7.  Genomic landscape of megakaryopoiesis and platelet function defects.

Authors:  Elisa Bianchi; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Rossella Manfredini
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

Review 8.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Authors:  S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

9.  LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.

Authors:  Baoming He; Ying Bai; Wei Kang; Xiaoping Zhang; Xiaojian Jiang
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

10.  Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Authors:  Ryo Shimizu; Tomoya Muto; Kazumasa Aoyama; Kwangmin Choi; Masahiro Takeuchi; Shuhei Koide; Nagisa Hasegawa; Yusuke Isshiki; Emi Togasaki; Chika Kawajiri-Manako; Yuhei Nagao; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Tohru Iseki; Daniel T Starczynowski; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko
Journal:  Leuk Res       Date:  2016-09-26       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.